Metadoxine Extended Release did not meet the primary endpoint in a study analysis for attention deficit hyperactivity disorder.
One of Alcobra’s candidate medications for attention deficit hyperactivity disorder, Metadoxine Extended Release, or MDX, did not meet the primary endpoint in a study analysis, according to a statement from the company.
The analysis reflected data on 283 adult patients enrolled in the phase 3 MEASURE clinical trial. The drug failed to demonstrate a statistically significant difference from placebo in the change from baseline of the investigator rating of the Conners’ Adult ADHD Rating Scales (CAARS).
"We are exceedingly disappointed with these top-line results," stated Dr. Yaron Daniely, President and CEO of Alcobra in a prepared statement. "We wish to reiterate our sincere appreciation to all of the patients, investigators, and others who aided us in conducting this study."